Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Iron Mountain Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Iron Mountain Inc trades at $122.75 (market cap $36.44B). The key difference: Iron Mountain Inc is the larger of the two by market cap, and Iron Mountain Inc pays a 2.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IRM | |
|---|---|---|
Market Cap | $29.60B | $36.44B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $133.06 |
52-Week Low | $205.48 | $78.86 |
Enterprise Value | $27.56B | $55.85B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Iron Mountain (IRM) trades at $124.55, up 2.46% on the day, with a bearish technical signal but strong recent earnings beats. Revenue growth is robust, reaching $6.90B in 2025, though net margins are thin at 5.54%. The stock shows high valuation multiples, including a P/E of 86.8, and carries significant debt, with total liabilities at $18.94B. Analyst consensus is bullish with a $141.50 price target, supported by institutional buying and positive Q2 2026 results highlighted by data center growth.
Outlook is cautiously optimistic due to earnings momentum and data center expansion, but high debt and declining paper storage pose risks. The stock offers potential upside to the consensus target, yet investors must weigh valuation concerns against operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
